A mutation that causes resistence to chemotherapy treatment of lung cancer has been discoveredSeptember 27, 1999Lung cancer, mainly caused by tobacco and inhaling radon gas, is the most lethal cancer in the western world. In Spain alone this disease causes around 15,000 deaths each year. One of the most effective treatments against the most widespread of variations, non small cell lung cancer, is the treatment with Paclitaxel, a medication that significantly increases the survival chances of 45% of those affected. Paclitaxel works by blocking the beta-tubulin action, a protein that actively participates in the cell cicle constructing, by coupling with the alfa-tubulin, networks of microtubules that, among other things, allow the development of cell division. If the tubulin units do not couple correctly, such as happens when Paclitaxel is used, the cell cicle is interrupted. This prevents tumors from growing. However, there is still a significant percentage of patients who do not respond at all to this treatment. A research team headed by Universitat Autònoma de Barcelona researchers and the Germans Trias i Pujol Hospital in Badalona, along with the participation by scientists at the Universidad Aut'³noma de Madrid, the Hospital Cl'nico de Madrid, Hospital Arnau de Vilanova, Valencia, and the Anderson Cancer Center, Houston in the US, have identified the mechanism that causes resistance to Paclitaxel. The researchers have observed that when patients show mutations in the gene that codifies beta-tubulin, a situation which happens in 30% of the cases, chemotherapy with Paclitaxel is completely ineffective. The mutations affect the dynamics of the microtubules in such a way that the medication cannot interrupt the cell cycle nor, consequently, the growth of tumors. Therefore, the mutations in the gene that codifies the beta-tubulin represent a new resistence mechanism to chemotherapy with Paclitaxel that, according to statements by the researchers, could have more general implications concerning the survival of tumors being treated by chemotherapy. So, this discovery, recently published in the Journal of Clinical Oncology, could mean an improvement in the prognosis of the response and survival of persons with lung cancer faced with different therapy options. Barcelona, Universitat Autònoma de |
|||||||||||||||||||||
| Related Lung Cancer Current Events and Lung Cancer News Articles Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Common pain relief medication may encourage cancer growth Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Study raises concerns about outdoor second-hand smoke Indoor smoking bans have forced smokers at bars and restaurants onto outdoor patios, but a new University of Georgia study in collaboration with the Centers for Disease Control and Prevention suggests that these outdoor smoking areas might be creating a new health hazard. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Preventative brain radiation for lung cancer patients: Benefits and risks A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Intervals between lung cancer diagnosis and treatment displays a health care disparity Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. More Lung Cancer Current Events and Lung Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||